News for SAGE Therapeutics Stock (SAGE)

Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

Business Wire • 07/17/24

The Schall Law Firm Encourages Investors With Losses To Initiate Dialogue, Sage Therapeutics Inc Is Under Scrutiny For Potential Securities Violations

Accesswire • 07/16/24

Sage Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Breaches Urging Investors With Losses To Start Conversation

Accesswire • 07/15/24

The Schall Law Firm Begins Investigation Into Sage Therapeutics Inc For Potential Securities Violations And Urges Investors With Losses To Initiate Conversation

Accesswire • 07/13/24

Inquiry Into Sage Therapeutics Inc For Possible Securities Breaches Initiated By The Schall Law Firm Encouraging Investors With Losses To Start Dialogue

Accesswire • 07/12/24

The Schall Law Firm Initiates Inquiry Into Sage Therapeutics Inc For Potential Securities Violations And Encourages Investors With Losses To Establish Dialogue

Accesswire • 07/10/24

The Schall Law Firm Starts Investigation Into Sage Therapeutics Inc For Possible Securities Breaches And Urges Investors With Losses To Set Up Communication

Accesswire • 07/09/24

The Schall Law Firm Initiates Probe Into Sage Therapeutics Inc For Potential Securities Violations And Encourages Investors With Losses To Establish Communication

Accesswire • 07/08/24

The Schall Law Firm Begins Investigation Into Sage Therapeutics Inc For Suspected Securities Breaches And Promotes Investors With Losses To Get In Touch

Accesswire • 07/07/24

The Schall Law Firm Is Conducting An Inquiry Into Sage Therapeutics Inc For Likely Securities Infringements And Invites Impacted Investors To Reach Out

Accesswire • 07/06/24

The Schall Law Firm Initiates Examination Into Sage Therapeutics Inc For Possible Securities Violations And Encourages Affected Investors To Establish Contact

Accesswire • 07/05/24

The Schall Law Firm Probes Sage Therapeutics Inc For Potential Securities Breaches And Urges Impacted Investors To Connect

Accesswire • 07/03/24

Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Violations Of Securities Laws And Investors Who Incurred Losses Are Encouraged To Reach Out

Accesswire • 07/02/24

The Schall Law Firm Is Investigating Sage Therapeutics Inc For Potential Infringements Of Securities Laws And Encourages Investors Who Sustained Losses To Make Contact

Accesswire • 06/28/24

The Schall Law Firm Is Probing Sage Therapeutics Inc For Possible Breaches Of Securities Regulations And Urges Investors Who Endured Losses To Reach Out

Accesswire • 06/26/24

Sage Therapeutics Inc Is Being Probed By The Schall Law Firm For Potential Securities Law Violations And Investors With Losses Are Encouraged To Reach Out

Accesswire • 06/25/24

Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Law Breaches And Investors With Losses Are Urged To Connect

Accesswire • 06/24/24

The Schall Law Firm Investigates Sage Therapeutics Inc For Potential Violations Of Securities Laws And Encourages Investors Who Have Suffered Losses To Get In Touch

Accesswire • 06/23/24

The Schall Law Firm Probes Sage Therapeutics Inc For Possible Breaches Of Securities Laws And Invites Loss Suffering Investors To Connect With The Firm

Accesswire • 06/22/24

The Schall Law Firm Is Investigating Sage Therapeutics Inc For Potential Violations Of Securities Laws Investors With Losses Are Encouraged To Contact The Firm

Accesswire • 06/19/24

Sage Therapeutics Inc Is Being Probed By The Schall Law Firm For Possible Securities Breaches Investors Who Have Suffered Losses Are Urged To Reach Out

Accesswire • 06/18/24

Sage Therapeutics Inc. Under Investigation By Schall Law Firm For Potential Securities Violations. Investors Who Lost Money Encouraged To Contact The Firm

Accesswire • 06/17/24

SAGE's Huntington's Disease Study Meets Primary Endpoint

Zacks Investment Research • 06/12/24

Allegations Against Sage Therapeutics, Inc.: Schall Law Firm Initiates Probe And Encourages Impacted Investors To Reach Out

Accesswire • 06/11/24

Sage Therapeutics' rare disease drug meets main goal in mid-stage study

Reuters • 06/11/24